Breaking News Instant updates and real-time market news.

TRXC

TransEnterix

$1.46

-0.01 (-0.68%)

, PETX

Aratana Therapeutics

17:19
10/13/17
10/13
17:19
10/13/17
17:19

On The Fly: After Hours Movers

HIGHER: TransEnterix (TRXC), up 63.7% after it confirmed that the FDA granted 510k clearance to its Senhance Surgical Robotic System... Aratana Therapeutics (PETX), up 8.8% after it announced the launch of ENTYCE... TerraForm Power (TERP), up 1.7% after it announced a stock oversubscription in its merger consideration election... Hershey (HSY), up 0.8% after CNBC reported that the company is expected to submit an initial bid for Nestle's (NSRGY) U.S. confectionery business. LOWER: Natural Health Trends (NHTC), down 10.2% after it reported preliminary third quarter revenue... Lipocine (LPCN), down 8% after it filed a $150M mixed securities shelf... Intuitive Surgical (ISRG), down 3.9% after TransEnterix's Senhance Surgical Robotic System received FDA clearance.

TRXC

TransEnterix

$1.46

-0.01 (-0.68%)

PETX

Aratana Therapeutics

TERP

TerraForm Power

$12.00

-0.6 (-4.76%)

HSY

Hershey

$110.07

0.1 (0.09%)

NSRGY

Nestle

$87.09

0.525 (0.61%)

NHTC

Natural Health Trends

$24.93

0.24 (0.97%)

LPCN

Lipocine

$3.99

-0.16 (-3.86%)

ISRG

Intuitive Surgical

$362.29

-0.24 (-0.07%)

  • 19

    Oct

  • 26

    Oct

  • 03

    Nov

  • 06

    Nov

TRXC TransEnterix
$1.46

-0.01 (-0.68%)

07/10/17
STFL
07/10/17
NO CHANGE
STFL
Surgeon, hospital happy with TransEnterix product, says Stifel
After observing the use of TransEnterix's Senhance robotic system at a German hospital, Stifel analyst Rick Wise says that the " surgeon and hospital are highly satisfied with and excited by their early experience" with the product. The analyst is "extremely enthusiastic" about the product and keeps a $4 price target and a Buy rating on the shares.
06/15/17
STFL
06/15/17
NO CHANGE
Target $4
STFL
Buy
TransEnterix first Japanese sale 'highly encouraging,' says Stifel
Stifel analyst Rick Wise views TransEnterix's first Japanese Senhance System sale as "highly encouraging" for the potential of global adoption. While Senhance is currently not approved for sale in Japan, the deal suggests a high level of clinician interest in the region, Wise tells investors in a research note. He believes Senhance approval in the U.S. remains the "most critical near-term value creating event" for TransEnterix. The analyst keeps a Buy rating on the shares with a $4 price target.
05/11/17
STFL
05/11/17
NO CHANGE
STFL
TransEnterix results highlights positive data points, says Stifel
Stifel analyst Rick Wise identified several positive data points in TransEnterix's Q1 results. Among these are the performance of 125 Senhance procedures in Europe, representing an acceleration of growth versus Q4, and the conversion of most of these procedures "from what would have been a laparoscopic approach." The analyst keeps a $4 price target and a Buy rating on the stock.
05/11/17
RILY
05/11/17
DOWNGRADE
Target $0.7
RILY
Neutral
TransEnterix downgraded to Neutral from Buy at B. Riley
B. Riley analyst Greg Chodaczek downgraded TransEnterix to Neutral and cut his price target for the shares to 70c from $2.75 citing a lack of system sales following the company's Q1 results.
PETX Aratana Therapeutics

02/06/17
STFL
02/06/17
DOWNGRADE
STFL
Hold
Aratana Therapeutics downgraded to Hold from Buy at Stifel
04/13/17
JEFF
04/13/17
NO CHANGE
Target $8
JEFF
Buy
Zoetis deal for Nexvet suggests $9 per share value for Aratana, says Jefferies
After Zoetis (ZTS) announced a deal to buy Nexvet Biopharma for $85M, Jefferies analyst David Gu said the multiple for the deal would suggest a $9 per share valuation for Aratana Therapeutics (PETX), which is also innovative companion animal biotech company. The analyst, who thinks Aratana's Entyce and Nocita would complement the portfolios of an acquirer, keeps a Buy rating and $8 price target on Aratana shares.
TERP TerraForm Power
$12.00

-0.6 (-4.76%)

02/03/17
MACQ
02/03/17
DOWNGRADE
MACQ
Neutral
TerraForm Power downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Angie Storozynski downgraded TerraForm Power (TERP) to Neutral and lowered its price target to $12 from $14 saying the $12 cash offer from Brookfield Asset Management (BAM) is disappointing. The analyst said TerraForm is heavily over-levered and interest and principal payments pressure the company's CAFD. He believes an equity injection from a new owner would boost cash flow generation but said it would require an investor with available cash and one willing to deal with TerraForm's complexity.
02/14/17
UBSW
02/14/17
UPGRADE
Target $11.5
UBSW
Neutral
TerraForm Power upgraded to Neutral from Sell at UBS
UBS analyst Julien Dumoulin-Smith upgraded TerraForm Power (TERP) to Neutral saying the risk/reward is now balanced with shares at his unchanged price target of $11.50. Further share moves are largely dependent on the company's ongoing strategic review, including prospects for an acquisition, Dumoulin-Smith tells investors in a research note. He believes the company's fundamentals are intact and feels Brookfield's (BAM) cash bids of $11.50 per share for TerraForm Power alone provides a support level for shares while the $12 per share level including TerraForm Global (GLBL) provides "some viable upside."
03/07/17
AVON
03/07/17
UPGRADE
Target $14
AVON
Outperform
TerraForm Power upgraded to Outperform from Market Perform at Avondale
Avondale analyst Michael Morosi upgraded TerraForm Power to Outperform with a $14 price target.
03/08/17
BMOC
03/08/17
NO CHANGE
BMOC
Brookfield Renewable acquisition seen as accretive at BMO Capital
BMO Capital analyst Ben Pham expects Brookfield Renewable's (BEP) acquisition of a 51% stake in TerraForm Power (TERP) and its acquisition of 100% of TerraForm Global (GLBL) to be accretive. The analyst adds that the deal " should relieve some pressure on the payout ratio." He reiterates a $33 price target and an Outperform rating on Brookfield Renewable.
HSY Hershey
$110.07

0.1 (0.09%)

08/17/17
BERN
08/17/17
UPGRADE
BERN
Outperform
Hershey upgraded to Outperform from Market Perform at Bernstein
08/17/17
08/17/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Buy from Neutral at MKM Partners. 2. Hershey (HSY) upgraded to Outperform from Market Perform at Bernstein with analyst Alexia Howard saying lower input costs could boost the company's gross margins heading into 2018. 3. EnerSys (ENS) upgraded to Buy from Neutral at Sidoti with analyst citing the recent pullback in shares and maintained an $83 price target. 4. Mosaic (MOS) upgraded to Hold from Sell at Vertical Research with analyst Sandy Klugman citing valuation. 5. Regency Centers (REG) upgraded to Top Pick from Outperform at RBC Capital with analyst Wes Golladay saying that Regency has "one of the best portfolios amongst the shopping center REITs." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/18/17
SBSH
08/18/17
NO CHANGE
Target $126
SBSH
Buy
Citi says Hershey meetings support bullish thesis
Citi analyst David Driscoll says he left meetings with management with increased confidence in Hershey's story. The company's "Margin for Growth" cost savings provide good visibility into its high single digit earnings target over the next three years, Driscoll tells investors in a research note. The analyst keeps a Buy rating on the shares with a $126 price target.
08/17/17
BERN
08/17/17
UPGRADE
BERN
Outperform
Hershey upgraded on lower input costs at Bernstein
As noted earlier, Bernstein upgraded Hershey to Outperform from Market Perform. Analyst Alexia Howard believes that lower input costs could boost the company's gross margins heading into 2018. She expects the U.S. chocolate category to grow modestly going forward, driven by millenials' love of snacking and increased innovation. Target to $127 from $109.
NSRGY Nestle
$87.09

0.525 (0.61%)

06/26/17
JPMS
06/26/17
NO CHANGE
JPMS
JPMorgan sees Kraft, Conagra, Dean rallying on Nestle speculation
JPMorgan analyst Ken Goldman expects Third Point's desire for Nestle (NSRGY) to divest assets to have an impact on shares of U.S. food producers. The analyst expects shares of Kraft Heinz (KHC), Conagra Brands (CAG) and Dean Foods (DF) to rally today on hopes of a potential accretive deal for some of Nestle's assets. The analyst thinks General Mills (GIS) shares may drop slightly on speculation that Nestle sells Cereal Partners Worldwide, which he believes would hinder the company's ability to grow cereal internationally. General Mills has a global partnership with Nestle via Cereal Partners Worldwide. Goldman also thinks Pinnacle Foods (PF) could trade down slightly with Conagra having "another potential dance partner" to do a deal.
08/16/17
PIPR
08/16/17
NO CHANGE
Target $92
PIPR
Neutral
Kraft Heinz could have interest in Nestle divestitures, says Piper Jaffray
Piper Jaffray analyst Michael Lavery expects Kraft Heinz (KHC) to pursue further consolidation, likely in packaged food, and believes potential divestitures from Nestle (NSRGY) could fit the company's criteria well. Such a deal could boost Kraft's international scale and provide synergy savings in its U.S. frozen supply chain, the analyst tells investors in a research note. He maintains a Neutral rating on Kraft Heinz shares with a $92 price target.
10/04/17
MSCO
10/04/17
NO CHANGE
Target $62
MSCO
Overweight
'Third Wave' coffee shops still too small to hurt Starbucks, says Morgan Stanley
Morgan Stanley analyst John Glass said the emergence of more "Third Wave" coffee shops have fueled competitive fears for Starbucks (SBUX), but he contends that the absolute numbers of specialty chains with 10 or more units remain small and most data sources show smaller chains and independents are flat to slightly declining in number. Recent high profile investments in specialty coffee, such as JAB's purchases of Stumptown and Intelligentsia and Nestle's (NSRGY) majority stake in Blue Bottle, are making headlines, but the brands' competitive relevance may be overstated, Glass tells investors. The analyst, who added that the last time McDonald's (MCD) pushed into specialty coffee it had "no discernable negative impact on Starbucks, and arguably even a positive one," keeps an Overweight rating and $62 price target on Starbucks shares.
10/13/17
CHLM
10/13/17
NO CHANGE
Target $7
CHLM
Buy
Market just beginning to recognize Codexis opportunity, says Craig-Hallum
Craig-Hallum analyst Matt Hewitt says Codexis (CDXS) has a "unique proprietary CodeEvolver protein engineering platform" that is being sought by large pharma names, citing yesterday's announcement of a partnership with Nestle (NSRGY). Hewitt says that despite the recent stock price appreciation, the increasing value of the company's development pipeline suggests the markets is just starting to recognize the opportunity. The analyst has a Buy rating and a $7 price target on the stock.
NHTC Natural Health Trends
$24.93

0.24 (0.97%)

LPCN Lipocine
$3.99

-0.16 (-3.86%)

06/20/17
ADAM
06/20/17
NO CHANGE
Target $11
ADAM
Buy
Lipocine data sets path toward FDA submission, says Canaccord
Canaccord analyst Dewey Steadman noted Lipocine reported positive top-line data for its dosing validation and dosing flexibility studies, which were required for the resubmission of its oral testosterone NDA. The analyst sees a resubmission in Q3 and believes the company has sufficient capital to meet near-term needs while the company plans to partner the drug. Steadman reiterated his Buy rating and raised his price target to $11 from $10 on Lipocine shares.
12/20/16
ADAM
12/20/16
INITIATION
Target $15
ADAM
Buy
Lipocine assumed with a Buy at Canaccord
Canaccord analyst Dewey Steadman assumed Lipocine with Buy and $15 price target citing its status as one of the leading companies developing oral testosterone replacement therapies to treat hypogonadism.
02/21/17
ROTH
02/21/17
NO CHANGE
Target $38
ROTH
Buy
Lipocine price target raised to $38 from $30 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Lipocine to $38 from $30 following clarity on LPCN-1107's pivotal trial design. The analyst reiterates a Buy rating on the shares.
ISRG Intuitive Surgical
$362.29

-0.24 (-0.07%)

10/10/17
WEDB
10/10/17
NO CHANGE
Target $395
WEDB
Outperform
Intuitive Surgical price target raised to $395 from $353 at Wedbush
Wedbush analyst Tao Levy raised his price target for Intuitive Surgical to $395 from $353 due to rolling forward of estimates, higher relative multiples, and healthy underlying company fundamentals. He reiterates an Outperform rating on the shares.
10/03/17
SBSH
10/03/17
NO CHANGE
SBSH
Citi's general surgery survey 'very positive' for Intuitive Surgical
Citi analyst Amit Hazan says his firm's general surgery survey is "very positive" for Intuitive Surgical (ISRG), and "much less so" for Medtronic (MDT) and Johnson & Johnson (JNJ). Robotic procedures are expected to be up about 30% this year and next, with ventral hernia leading, Hazan tells investors in a research note partially titled "It's a Good Time to be a Robot." He believes robotic is really starting to hurt laparoscopy and that Medtronic and J&J will likely be forced to talk about the headwind publicly.
09/25/17
WEDB
09/25/17
NO CHANGE
Target $1060
WEDB
Outperform
Conservative outlook on Intuitive da Vinci SP adoption warranted, says Wedbush
Wedbush analyst Tao Levy remains constructive on Intuitive Surgical's "robust," underlying growth prospects and fundamentals, but believes an initial conservative outlook on the adoption of the da Vinci SP platform is warranted during the first few years following commercialization, which is expected in 2018. While management has not provided any guidance related to the platform's potential revenue contribution, the analyst believes Intuitive Surgical's share price partly reflects investor expectations of a successful launch of the SP. He reiterates an Outperform rating and $1,060 price target on the shares.
09/05/17
MSCO
09/05/17
NO CHANGE
Target $1150
MSCO
Overweight
Intuitive Surgical price target raised to $1,150 from $1,070 at Morgan Stanley
Morgan Stanley analyst David Lewis raised his price target on Intuitive Surgical to $1,150 from $1,070 as he contends that the flexible catheter system in development through a joint venture with Fosun could disrupt the $6B lung biopsy market. The analyst, who estimates the FC system could be worth $80-$175 per share for Intuitive, reiterates his Overweight rating on the stock.

TODAY'S FREE FLY STORIES

SAGE

Sage Therapeutics

$61.43

0.08 (0.13%)

14:51
10/17/17
10/17
14:51
10/17/17
14:51
Conference/Events
Sage Therapeutics management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

S

Sprint

$7.10

-0.05 (-0.70%)

14:50
10/17/17
10/17
14:50
10/17/17
14:50
Options
$7M put buyer in Sprint »

$7M put buyer in Sprint.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 16

    May

IBM

IBM

$146.51

-0.32 (-0.22%)

14:49
10/17/17
10/17
14:49
10/17/17
14:49
Options
IBM options imply 5.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

STZ

Constellation Brands, also tag STZ.B

$212.29

1.84 (0.87%)

14:46
10/17/17
10/17
14:46
10/17/17
14:46
Conference/Events
Constellation Brands, also tag STZ.B management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

SVU

Supervalu

$18.90

0.085 (0.45%)

14:40
10/17/17
10/17
14:40
10/17/17
14:40
Options
Short-term call buying in SuperValu as shares slip into earnings »

Short-term call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

HES

Hess Corp.

$45.67

-0.37 (-0.80%)

14:30
10/17/17
10/17
14:30
10/17/17
14:30
Options
Hefty spread in Hess as a bullish position is adjusted »

Hefty spread in Hess as a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

DAL

Delta Air Lines

$52.91

-0.71 (-1.32%)

, MSG

Madison Square Garden

$215.84

-1.91 (-0.88%)

14:27
10/17/17
10/17
14:27
10/17/17
14:27
Hot Stocks
Delta expands MSG, MSG Networks partnership »

Delta (DAL) has renewed…

DAL

Delta Air Lines

$52.91

-0.71 (-1.32%)

MSG

Madison Square Garden

$215.84

-1.91 (-0.88%)

MSGN

MSG Networks

$21.03

0.275 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

MOH

Molina Healthcare

$61.64

1.78 (2.97%)

, UNH

UnitedHealth

$205.36

12.16 (6.29%)

14:27
10/17/17
10/17
14:27
10/17/17
14:27
Periodicals
Senator says bipartisan deal reached to stabilize ObamaCare, The Hill reports »

Republican Senator Lamar…

MOH

Molina Healthcare

$61.64

1.78 (2.97%)

UNH

UnitedHealth

$205.36

12.16 (6.29%)

CNC

Centene

$93.61

2.6901 (2.96%)

WCG

WellCare

$173.81

5.89 (3.51%)

CI

Cigna

$188.26

3.27 (1.77%)

ANTM

Anthem

$189.00

5.24 (2.85%)

HNT

Health Net

HUM

Humana

$241.96

4.785 (2.02%)

AET

Aetna

$155.62

4.18 (2.76%)

THC

Tenet

$13.31

0.4 (3.10%)

UHS

Universal Health

$108.19

2.59 (2.45%)

LPNT

LifePoint

$55.80

0.8 (1.45%)

HCA

HCA Healthcare

$77.14

1.95 (2.59%)

CYH

Community Health

$6.13

0.23 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

14:25
10/17/17
10/17
14:25
10/17/17
14:25
General news
Fed discount rate meeting minutes: 11 of 12 Banks voted for an unchanged »

Fed discount rate meeting…

ORI

Old Republic

$19.53

-0.24 (-1.21%)

14:21
10/17/17
10/17
14:21
10/17/17
14:21
Hot Stocks
Breaking Hot Stocks news story on Old Republic »

Old Republic trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTN

Vail Resorts

$218.22

1.7975 (0.83%)

14:20
10/17/17
10/17
14:20
10/17/17
14:20
Options
Call buyers in Vail Resorts as shares see strength »

Call buyers in Vail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

SVU

Supervalu

$18.77

-0.04 (-0.21%)

14:18
10/17/17
10/17
14:18
10/17/17
14:18
Technical Analysis
Technical Earnings Preview: Supervalu at multi-year lows ahead of results »

The stock has been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

$NSD

NASDAQ Market Internals

14:17
10/17/17
10/17
14:17
10/17/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$39.76

0.09 (0.23%)

, NVDA

Nvidia

$197.93

3.34 (1.72%)

14:16
10/17/17
10/17
14:16
10/17/17
14:16
Periodicals
Intel unveils new family of chips to take on Nvidia in AI, The Verge says »

Intel (INTC) has unveiled…

INTC

Intel

$39.76

0.09 (0.23%)

NVDA

Nvidia

$197.93

3.34 (1.72%)

SFTBF

SoftBank

$89.80

0.9 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 30

    Oct

  • 01

    Nov

$NYE

NYSE Market Internals

14:16
10/17/17
10/17
14:16
10/17/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORI

Old Republic

$19.53

-0.245 (-1.24%)

14:11
10/17/17
10/17
14:11
10/17/17
14:11
Hot Stocks
Old Republic says Q3 to include operating charges of $150M »

Old Republic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVI

Navient

$11.73

0.11 (0.95%)

14:10
10/17/17
10/17
14:10
10/17/17
14:10
Options
Call buyers in Navient ahead of earnings »

Call buyers in Navient…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

UNP

Union Pacific

$110.09

-2 (-1.78%)

14:08
10/17/17
10/17
14:08
10/17/17
14:08
Periodicals
Breaking Periodicals news story on Union Pacific »

Union Pacific initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

PACW

PacWest Bancorp

$48.09

0.13 (0.27%)

14:05
10/17/17
10/17
14:05
10/17/17
14:05
Downgrade
PacWest Bancorp rating change  »

PacWest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 09

    Nov

  • 13

    Nov

  • 14

    Nov

MOH

Molina Healthcare

$60.74

0.88 (1.47%)

, UNH

UnitedHealth

$204.93

11.73 (6.07%)

14:01
10/17/17
10/17
14:01
10/17/17
14:01
Periodicals
Senator Alexander says deal reached to shore up ACA markets, Bloomberg says »

Bloomberg cites Senator…

MOH

Molina Healthcare

$60.74

0.88 (1.47%)

UNH

UnitedHealth

$204.93

11.73 (6.07%)

CNC

Centene

$92.84

1.92 (2.11%)

WCG

WellCare

$172.72

4.8 (2.86%)

CI

Cigna

$187.49

2.5 (1.35%)

ANTM

Anthem

$187.60

3.8392 (2.09%)

HNT

Health Net

HUM

Humana

$241.08

3.905 (1.65%)

AET

Aetna

$155.17

3.7303 (2.46%)

HCA

HCA Healthcare

$75.63

0.44 (0.59%)

CYH

Community Health

$5.97

0.065 (1.10%)

THC

Tenet

$12.79

-0.12 (-0.93%)

UHS

Universal Health

$106.78

1.18 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

ORI

Old Republic

$19.54

-0.23 (-1.16%)

14:01
10/17/17
10/17
14:01
10/17/17
14:01
Hot Stocks
Breaking Hot Stocks news story on Old Republic »

Old Republic trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$128.76

1.035 (0.81%)

14:00
10/17/17
10/17
14:00
10/17/17
14:00
Hot Stocks
Deere wins trademark lawsuit against FIMCO »

U.S. District Court in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

XLF

Financial Select Sector

$26.13

-0.17 (-0.65%)

14:00
10/17/17
10/17
14:00
10/17/17
14:00
Options
Whale of a trade in SPDR Financial ETF expresses a defensive view »

Whale of a trade in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

13:47
10/17/17
10/17
13:47
10/17/17
13:47
Periodicals
Amazon inks deals with apartment landlords for lockers, WSJ reports »

Amazon.com has signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

WMT

Wal-Mart

$85.81

0.065 (0.08%)

13:41
10/17/17
10/17
13:41
10/17/17
13:41
Periodicals
Wal-Mart's Lore: Company plans to acquire more startups, TechCrunch reports »

Wal-Mart eCommerce CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.